8 completed, 3 active not recruiting, 1 enrolling by invitation, 1 recruiting. 7 Phase 1, 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 4 | Active not recruiting 2, Enrolling by invitation 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow cenerimod: new trials by email Literature Review of cenerimod trials Research Report on cenerimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Cenerimod, Placebo - Nephritis, Lupus, Lupus Erythematosus, Systemic | Phase 3 | Recruiting | Viatris Innovation GmbH | 300 | 2026-02-09 | 2026-07-30 |
| A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) cenerimod 4 mg - SLE - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Viatris Pharmaceuticals Co., Ltd. | 15 | 2026-01-14 | 2026-07-28 |
| A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants Cenerimod (oral), 14C-Cenerimod (i.v.) - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 6 | 2025-12-11 | 2026-07-14 |
| Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus Cenerimod - Lupus Erythematosus, Systemic | Phase 3 | Enrolling by invitation | Viatris Innovation GmbH | 680 | 2024-07-30 | 2026-09-11 |
| A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Cenerimod, Placebo - Lupus Erythematosus, Systemic | Phase 3 | Active not recruiting | Viatris Innovation GmbH | 451 | 2023-06-26 | 2026-10-30 |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Cenerimod, Placebo - Lupus Erythematosus, Systemic | Phase 3 | Active not recruiting | Viatris Innovation GmbH | 470 | 2022-12-13 | 2026-10-30 |
| The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Cenerimod - Healthy, Renal Impairment | Phase 1 | Completed | Viatris Innovation GmbH | 16 | 2021-09-27 | 2025-09-22 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod Cenerimod - Healthy, Hepatic Impairment | Phase 1 | Completed | Viatris Innovation GmbH | 24 | 2021-08-25 | 2025-09-22 |
| To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 97 | 2020-01-31 | 2025-09-22 |
| Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects Cenerimod, Matching Placebo - Healthy Volunteers | Phase 1 | Completed | Viatris Innovation GmbH | 20 | 2019-08-07 | 2025-09-22 |
| Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg - Systemic Lupus Erythematosus | Phase 2 | Completed | Viatris Innovation GmbH | 427 | 2018-12-21 | 2026-07-29 |
| A Study to Evaluate Cenerimod in Healthy Male Subjects Cenerimod - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 6 | 2016-09-01 | 2025-09-22 |
| Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus Matching placebo, Cenerimod - Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Completed | Viatris Innovation GmbH | 105 | 2015-06-01 | 2026-07-29 |
Lupus Erythematosus, Systemic (7) · Connective Tissue Diseases (4) · Autoimmune Diseases (3) · Immune System Diseases (3) · Lupus Nephritis (1) · Renal Insufficiency (1) · Skin and Connective Tissue Diseases (1)
Viatris Innovation GmbH (12) · Viatris Pharmaceuticals Co., Ltd. (1)
United States (7) · Ukraine (5) · Bulgaria (4) · France (4) · Georgia (4) · Mexico (4) · Philippines (4) · Poland (4) · Portugal (4) · Chile (3) · Czechia (3) · Germany (3) · Greece (3) · Puerto Rico (3) · Romania (3)
PMID 39586304, PMID 31798918, PMID 39919901
2018 (1), 2019 (1)